Top experts from Amgen, CBIZ & Intrepid discuss 2025 trends in healthcare, biotech, and life sciences. Explore key insights ...

Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

President Donald Trump's proposed budget cuts to the National Institutes of Health would eventually result in fewer drugs on ...

The Trump administration’s proposed cuts to medical research and health agencies will curtail the development of promising ...

Recent developments in the health sector highlight diverse changes from drug pricing initiatives by Bristol Myers and Pfizer ...

The UK government has revealed a plan to open a biosecurity facility in Harlow, Essex, to help protect the country from ...

Pfizer, in partnership with Bristol Myers Squibb, has launched a direct-to-patient sales strategy for Eliquis®, aiming to ...

Hong Kong-based Sino Biopharm, which took its stake in LaNova when it participated in the company's $42 million financing ...

As different stocks rise and fall, so do dividend yields, creating a shifting landscape of opportunities for income-oriented ...

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

Pfizer has caught investors’ eyes recently, outperforming its peers slightly but facing modest growth prospects ahead.

Recent health news highlights various developments, including Trump's spending bill impacting insurance costs, a major acquisition in the bioscience sector, and GSK's efforts to expand RSV vaccine ...